P Raskin

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
    Philip Raskin
    University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2598-603. 2003
  2. ncbi Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes
    P Raskin
    University of Texas Southwest Medical Center, Dallas 75390, USA
    Diabetes Care 23:979-83. 2000
  3. ncbi A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Diabetes Care 24:1226-32. 2001
  4. ncbi Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:947-52. 2009
  5. ncbi Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:865-73. 2009
  6. ncbi Weight gain in type 2 diabetes mellitus
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 9:386-93. 2007
  7. ncbi Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
    P Raskin
    Department of Internal Medicine, Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 10:1167-77. 2008
  8. ncbi Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 11:27-32. 2009
  9. ncbi Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone
    P Raskin
    University of Texas, South Western Medical Center, Dallas, TX, USA
    Diabet Med 21:329-35. 2004
  10. ncbi A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    J Diabetes Complications 15:295-300. 2001

Detail Information

Publications65

  1. ncbi Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
    Philip Raskin
    University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2598-603. 2003
    ..Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type 2 diabetes...
  2. ncbi Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes
    P Raskin
    University of Texas Southwest Medical Center, Dallas 75390, USA
    Diabetes Care 23:979-83. 2000
    ....
  3. ncbi A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Diabetes Care 24:1226-32. 2001
    ..To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy...
  4. ncbi Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:947-52. 2009
    ..To assess the efficacy and safety of a new repaglinide/metformin fixed-dose combination (FDC) tablet administered either twice a day (BID) or three times a day (TID) for the management of type 2 diabetes...
  5. ncbi Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 11:865-73. 2009
    ..To assess the use of a new repaglinide/metformin fixed-dose combination (FDC) tablet for the treatment of type 2 diabetes...
  6. ncbi Weight gain in type 2 diabetes mellitus
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 9:386-93. 2007
    ..To investigate the potential causes of weight gain using insulin and combination therapy in type 2 diabetes...
  7. ncbi Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
    P Raskin
    Department of Internal Medicine, Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 10:1167-77. 2008
    ..The combination regimen of repaglinide plus metformin should therefore be considered as a valuable option in the management of patients with type 2 diabetes when monotherapy is no longer adequate...
  8. ncbi Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 11:27-32. 2009
    ....
  9. ncbi Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone
    P Raskin
    University of Texas, South Western Medical Center, Dallas, TX, USA
    Diabet Med 21:329-35. 2004
    ....
  10. ncbi A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump
    P Raskin
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, G5-238, Dallas, TX 75390-8858, USA
    J Diabetes Complications 15:295-300. 2001
    ..When used in external pumps, insulin lispro provides better glycemic control than buffered regular human insulin with a similar adverse event profile...
  11. ncbi Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    P Raskin
    Southwestern Medical Center at Dallas, University of Texas, 75390 8858, USA
    Diabetes Care 23:583-8. 2000
    ..The improvement was not obtained at an increased risk of hypoglycemia. HbA1c was slightly, but significantly, lower for IAsp compared with HI at 6 and 12 months...
  12. ncbi Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 31:2177-82. 2008
    ....
  13. ncbi Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience
    A Piñero-Piloña
    Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Diabetes Care 24:1014-8. 2001
    ....
  14. ncbi Idiopathic Type 1 diabetes
    A Piñero-Piloña
    Department of Internal Medicine, University of Texas Southwestern Medical School, G4 100, 5323 Harry Hines Boulevard, Dallas, TX 75390 8858, USA
    J Diabetes Complications 15:328-35. 2001
    ..Although the pathogenesis of this disease is unknown, it may be related to lipotoxicity, glucose toxicity or transcription factors involved in fuel metabolism...
  15. ncbi Improved glycemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses
    S M Strowig
    University of Texas Southwestern Medical Center, Department of Internal Medicine, Dallas 75235 8858, USA
    Diabetes Care 21:1694-8. 1998
    ..To determine the effect on glycemic control in intensively treated type 1 diabetic patients using a blood glucose meter with storage capability and computer-assisted analyses...
  16. ncbi The visceral and subcutaneous fat changes in type 1 diabetes: a pilot study
    A N Jacob
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8858, USA
    Diabetes Obes Metab 8:524-30. 2006
    ..The correlation between the changes in ghrelin and the visceral to subcutaneous fat ratios is intriguing, but a larger study may be needed to confirm this finding...
  17. ncbi Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Diabetes Obes Metab 14:163-73. 2012
    ..This study evaluated pulmonary function changes in diabetes patients receiving inhaled Technosphere Insulin (TI) or usual antidiabetes treatment (usual care)...
  18. ncbi Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
    Anders Lindholm
    Novo Nordisk, Bagsvaerd, Denmark
    Diabetes Care 25:876-82. 2002
    ....
  19. ncbi Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka
    Philip Raskin
    Diabetes Care 28:2811. 2005
  20. ncbi Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus
    Larissa Aviles-Santa
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 75390 8858, USA
    J Investig Med 54:20-31. 2006
    ....
  21. ncbi Efficacy of biphasic insulin aspart in patients with type 2 diabetes
    Serge Halimi
    Department d Urologie, Nephrologie et Endocrinologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
    Clin Ther 27:S57-74. 2005
    ..It would be expected that these pharmacokinetic improvements would enhance clinical performance. However, the efficacy of BIAsp 30 compared with other common treatment regimens has not yet been systematically reviewed...
  22. ncbi Comparison of type 1, type 2, and atypical ketosis-prone diabetes at 4 years of diabetes duration
    Maria A Ramos-Roman
    Department of Internal Medicine at the University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
    J Diabetes Complications 20:137-44. 2006
    ..Atypical ketosis-prone diabetes (KPD) is frequently detected in obese individuals at diagnosis of diabetes, yet its precise pathophysiology is not understood...
  23. ncbi Postprandial glucose and its role in type 2 diabetes
    Jaime Davidson
    Hormones (Athens) 5:1 p following 217. 2006
  24. ncbi Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues
    Meryl Brod
    The BROD GROUP, Mill Valley, CA 94941, USA
    Health Qual Life Outcomes 5:8. 2007
    ....
  25. ncbi Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted
    Ildiko Lingvay
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, TX 7390 8858, USA
    J Investig Med 55:62-8. 2007
    ..The aim of this study was to evaluate the feasibility, acceptability, and efficacy of insulin with metformin for newly diagnosed, treatment-naive patients with T2DM...
  26. ncbi Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes
    Philip Raskin
    University of Texas Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Metab Res Rev 24:3-13. 2008
    ..This manuscript presents the case that when insulin therapy is initiated it should be tailored to individual needs through combination with one or more insulin sensitizers rather than a secretagogue...
  27. ncbi Effects of multiple daily insulin injections on peripheral glucose disposal in Latin Americans with type 2 diabetes mellitus
    Larissa Aviles-Santa
    Department of Medicine, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd G5 238, Dallas, TX 75390 8858, USA
    J Investig Med 55:11-7. 2007
    ..To evaluate the effects of insulin in multiple daily injections (MDI) on peripheral glucose disposal in Latin American patients with type 2 diabetes...
  28. ncbi Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
    Ildiko Lingvay
    Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    J Diabetes Complications 21:137-42. 2007
    ..We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes...
  29. ncbi Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes
    Ivana Zib
    Division of Endocrinology, Diabetes and Metabolism, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8899, USA
    J Investig Med 55:230-6. 2007
    ..The addition of pioglitazone to insulin therapy reduced myocardial and hepatic steatosis, consistent with the reported ability of the thiazolidinedione agents to redistribute fat from nonadipose to subcutaneous adipose depots...
  30. ncbi Efficacy and safety of insulin detemir
    Philip Raskin
    Internal Medicine Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Endocrinol Metab Clin North Am 36:21-32. 2007
    ..Finally, an evaluation of these data serves to show how the highly predictable action of insulin detemir translates into effective glycemic control with a lower incidence of hypoglycemia...
  31. ncbi Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy
    William W Chance
    Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA
    Diabetes Care 31:1596-601. 2008
    ..We examined whether similar impairment develops in type 2 diabetes and defined the physiologic sources of impairment as well as the relationships to glycemia and systemic microangiopathy...
  32. ncbi Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus
    Suzanne M Strowig
    Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Diabetes Obes Metab 7:633-41. 2005
    ..The potential for metformin or the thiazolidinediones to impact long-term cardiovascular outcomes remains under investigation...
  33. ncbi PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin
    John Gerich
    General Clinical Research Center, University of Rochester, New York, USA
    Diabetes Care 28:2093-9. 2005
    ..CONCLUSIONS: Similar good glycemic control can be maintained for 2 years with either treatment regimen, but nateglinide/metformin may represent a safer approach to initial combination therapy...
  34. ncbi Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs
    Philip Raskin
    Department of Internal Medicine, Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
    Diabetes Care 28:260-5. 2005
    ..Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs)...
  35. ncbi Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Diabetes Care 25:439-44. 2002
    ..To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes...
  36. ncbi Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences
    Christopher A Newton
    The University Diabetes Treatment Center, Parkland Memorial Hospital, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 75390-8858, USA
    Arch Intern Med 164:1925-31. 2004
    ....
  37. ncbi Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes
    Patrick Litonjua
    University of Texas Southwestern Medical School, Department of Internal Medicine, Dallas, 75390, USA
    Endocr Pract 10:101-6. 2004
    ..Prevalence of acanthosis nigricans is influenced by ethnicity and BMI in this patient population...
  38. ncbi Improved glycemic control without weight gain using triple therapy in type 2 diabetes
    Suzanne M Strowig
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
    Diabetes Care 27:1577-83. 2004
    ..To evaluate the safety and effectiveness of triple therapy using insulin, metformin, and a thiazolidinedione following a course of dual therapy using insulin and metformin or insulin and a thiazolidinedione in type 2 diabetes...
  39. ncbi Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
    Charles Kilo
    Kilo Clinical Research, Limited, 1227 Fern Ridge Parkway, Suite 100, St Louis, MO 63141, USA
    J Diabetes Complications 17:307-13. 2003
    ..The results indicate that patients with T2DM can safely and effectively begin insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin...
  40. ncbi Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin
    Philip Raskin
    Departemtn of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2063-8. 2003
    ..An open-label, parallel-group, randomized, multicenter trial was conducted to compare efficacy and safety of repaglinide versus nateglinide, when used in a combination regimen with metformin for treatment of type 2 diabetes...
  41. ncbi Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes
    Suzanne M Strowig
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 8858, USA
    Diabetes Care 25:1691-8. 2002
    ..To evaluate the safety and efficacy of treatment with insulin alone, insulin plus metformin, or insulin plus troglitazone in individuals with type 2 diabetes...
  42. ncbi Can glycemic targets be achieved-- in particular with two daily injections of a mix of intermediate- and short-acting insulin?
    Philip Raskin
    University of Texas Southwestern Medical Center, Dallas, USA
    Endocr Pract 12:52-4. 2006
    ..To present data that demonstrate the feasibility of using twice-daily insulin injections, in combination with selected orally administered agents, to achieve glycemic targets in patients with type 2 diabetes...
  43. ncbi A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes
    William H Herman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0354, USA
    Diabetes Care 28:1568-73. 2005
    ..To compare the efficacy and safety of continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI) in older adults with insulin-treated type 2 diabetes and to assess treatment satisfaction and quality of life...
  44. ncbi Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus
    Alvin Huang
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8858, USA
    Treat Endocrinol 4:205-20. 2005
    ..Hepatic toxicity with currently available thiazolidinediones has been found to be minimal overall...
  45. ncbi The effect of rosiglitazone on overweight subjects with type 1 diabetes
    Suzanne M Strowig
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Care 28:1562-7. 2005
    ..To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes...
  46. ncbi The relationship between immune-mediated Type 1 diabetes mellitus and ethnicity
    Larissa Aviles-Santa
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Parkland Health and Hospital System 5323 Harry Hines Boulevard G5 238, Dallas, TX 75390 8858, USA
    J Diabetes Complications 18:1-9. 2004
    ..To determine the proportion of adults with newly diagnosed Type 1 diabetes that had immune-mediated disease (IMD)...
  47. ncbi Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  48. ncbi Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
    David M Nathan
    N Engl J Med 353:2643-53. 2005
    ..We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease...
  49. ncbi Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  50. ncbi The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial
    George L Bakris
    Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
    J Diabetes Complications 19:74-9. 2005
    ..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension...
  51. ncbi Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
    Prakash Deedwania
    Anesthesiology 109:14-24. 2008
    ..Although firm guidelines will need to await completion of these clinical trials, the present statement also provides consensus recommendations for hyperglycemia management in patients with ACS on the basis of the available data...
  52. ncbi Anemia associated with new-onset diabetes: improvement with blood glucose control
    Antonio Piñero-Piloña
    Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX 75390 8858, USA
    Endocr Pract 8:276-81. 2002
    ..To evaluate the mild normochromic normocytic anemia associated with new-onset diabetes in young, otherwise healthy patients...
  53. ncbi Diabetic hypertriglyceridemia-induced acute pancreatitis masquerading as biliary pancreatitis
    David B Huang
    University Diabetes Treatment Center, Parkland Memorial Hospital, Dallas, Texas, USA
    J Diabetes Complications 16:180-2. 2002
    ..Institution of insulin therapy caused a resolution of the hypertriglyceridemia and a cessation of the episodes of acute pancreatitis...
  54. ncbi Immune-mediated disease and secondary failure to oral therapy in type 2 diabetes mellitus
    Larissa Aviles-Santa
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, Parkland Health and Hospital System 5323 Harry Hines Boulevard G5 238, Dallas, TX 75390 8858, USA
    J Diabetes Complications 18:10-7. 2004
    ..To determine the proportion of adults with type 2 diabetes, who developed secondary failure to oral medications that had immune-mediated diabetes (IMD)...
  55. ncbi Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial
    Jay S Skyler
    University of Miami, School of Medicine, Miami, FL 33136, USA
    Diabetes Care 28:1630-5. 2005
    ..We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen...
  56. ncbi Anthropometric features and cardiovascular risk in young Latin Americans with type 2 diabetes mellitus
    Larissa Aviles-Santa
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, TX 75390 8858, USA
    J Diabetes Complications 20:69-74. 2006
    ..The purpose of this study is to compare score systems used to estimate the risk for cardiovascular disease (CVD) in young patients with poorly controlled type 2 diabetes...
  57. ncbi The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin
    Connie C W Hsia
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA
    Am J Med 118:205-11. 2005
    ..This article addresses the importance and pathophysiologic basis of diabetic pulmonary involvement, the assessment of diabetic alveolar microangiopathy, and the relevance of this understanding for the emerging use of inhaled insulin...
  58. ncbi Novel insulin analogues and its mitogenic potential
    Ivana Zib
    Department on Internal Medicine, Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX 75390 8858, USA
    Diabetes Obes Metab 8:611-20. 2006
    ....
  59. ncbi The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes
    Hiroshi Noto
    The University Diabetes Treatment Center, Parkland Memorial Hospital, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8858, USA
    J Diabetes Complications 20:343-8. 2006
    ..CONCLUSIONS: Our findings suggest that Lp-PLA(2) assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin...
  60. ncbi Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes
    Berrin Ergun-Longmire
    Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
    Ann N Y Acad Sci 1029:260-77. 2004
    ..If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion...
  61. ncbi Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..The effects of the 2 beta-blockers on clinical outcomes need to be compared in long-term clinical trials...
  62. ncbi Hepatitis C infection and diabetes
    Hiroshi Noto
    Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, TX 75390-8858, USA
    J Diabetes Complications 20:113-20. 2006
    ..Further clinical researches are awaited in order to effectively detect, prevent, and treat HCV-associated type 2 diabetes, which would also slow the progression of hepatitis C itself...
  63. ncbi Body weight changes with beta-blocker use: results from GEMINI
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
    Am J Med 120:610-5. 2007
    ....
  64. ncbi Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study
    Jonathan M McGavock
    Department of Internal Medicine, Divisions of Hypertension, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex, USA
    Circulation 116:1170-5. 2007
    ..Whether cardiac steatosis precedes the onset of cardiomyopathy in individuals with impaired glucose tolerance or in patients with type 2 diabetes mellitus is unknown...
  65. ncbi Glucagon-like peptide: the time is near
    Alvin Huang
    Basic Clin Pharmacol Toxicol 95:249-51. 2004